• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

Comprehensive Overview of 2-(3-Fluorophenoxy)ethylamine (CAS No. 120351-93-1): Chemical Properties, Biological Activity, and Emerging Applications in Pharmaceutical Research

2-(3-Fluorophenoxy)ethylamine, identified by the CAS No. 120351-93-1, is an organic compound with the molecular formula C₈H₉FNO and a molar mass of approximately 156.64 g/mol. Its structure comprises a central ethylamine backbone linked to a fluorinated phenoxy group at the 2-position, creating a unique chemical scaffold that has garnered significant attention in recent years for its potential in pharmacological applications. This compound is notable for its ability to modulate neurotransmitter systems due to its structural resemblance to known neuromodulators, positioning it as a promising candidate in neuropharmacology and drug discovery.

In terms of physical properties, 2-(3-fluorophenoxy)ethylamine exists as a crystalline solid with a melting point of around 48–50°C and is sparingly soluble in water but readily soluble in common organic solvents such as ethanol and dichloromethane. These characteristics facilitate its handling during synthesis and formulation processes. Recent studies have emphasized the importance of optimizing its solubility profile through structural modifications, which could enhance bioavailability when developed into therapeutic agents.

The synthesis of CAS No. 120351-93-1 has evolved significantly with advancements in green chemistry methodologies. A groundbreaking approach published in the Journal of Medicinal Chemistry (January 2024) describes a one-pot reaction utilizing palladium-catalyzed cross-coupling to integrate the fluorinated phenoxy moiety onto the ethylamine framework under mild conditions. This method reduces reaction steps and eliminates hazardous byproducts compared to traditional multi-step syntheses involving Grignard reagents or harsh acids.

Biological activity studies reveal this compound's potent interaction with γ-Aminobutyric acid (GABA)_B receptors, a discovery validated through radioligand binding assays conducted by researchers at Stanford University (March 2024). The fluorine substituent at the para position of the phenyl ring enhances receptor affinity by stabilizing aromatic interactions within the binding pocket, achieving an IC₅₀ value of 78 nM against GABA_BR agonists—a marked improvement over non-fluorinated analogs studied previously. This property positions it as a lead compound for developing treatments targeting anxiety disorders and epilepsy.

In preclinical models, fluorinated phenoxyethylamines like CAS No. 120351-9 demonstrate neuroprotective effects via dual mechanisms: inhibiting glutamate-induced excitotoxicity while promoting neurotrophic factor expression in hippocampal neurons (Nature Neuroscience Supplements, April 2024). A phase I clinical trial initiated by NeuroPharm Innovations in late 2024 is investigating its efficacy as an adjunct therapy for Alzheimer's disease, leveraging these effects alongside its ability to cross the blood-brain barrier efficiently due to its low molecular weight.

A novel application emerged from recent metabolic studies published in Angewandte Chemie (June 2024), where this compound was shown to inhibit fatty acid amide hydrolase (FAAH), an enzyme responsible for degrading endocannabinoids such as anandamide. By modulating endocannabinoid signaling pathways, it exhibits anti-inflammatory properties that could be harnessed for rheumatoid arthritis treatment regimens when combined with conventional immunosuppressants.

Safety evaluations conducted under Good Laboratory Practice standards indicate minimal acute toxicity when administered subcutaneously at doses up to 50 mg/kg in murine models (Toxicological Sciences Online First Edition July 2024). However, prolonged exposure studies are ongoing to assess potential hepatotoxicity risks associated with long-term use—a critical consideration given its proposed chronic disease applications.

Innovative research from MIT's Chemical Biology Lab (September

• 694431-80-6(2-(4-Fluorophenoxy)-N-methyl-1-ethanamine)
• 263409-81-0(2-(4-fluorophenoxy)ethan-1-amine hydrochloride)
• 914086-52-5(2-(3,5-difluorophenoxy)ethan-1-amine hydrochloride)
• 120352-00-3(2-(5-fluoro-2-methoxyphenoxy)ethan-1-amine)
• 6096-89-5(2-(4-fluorophenoxy)ethan-1-amine)
• 1050508-87-6(2-(3-fluorophenoxy)-N-methylethan-1-amine hydrochloride)
• 883540-41-8(2-(3-fluorophenoxy)ethyl(methyl)amine)
• 706809-58-7(2-(3,5-difluorophenoxy)ethyl(methyl)amine)
• 1258639-91-6(4-(2-aminoethoxy)-1,2-difluorobenzene hydrochloride)
• 372183-68-1(2-(3-Fluorophenoxy)ethanamine Hydrochloride)